Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on May 6th, 2023%
Technology intelligence company CB Insights says this week that psychedelic therapies and services are generating little interest among venture investors this year, with only nine deals totaling $21 million. . . . → Read More: Infographic – Psychedelics Funding Coming Down
By Alan, on May 4th, 2023%
The first participant in a clinical trial received a dose of a psychedelic therapy, assessing the experimental compound in people with treatment resistant depression. . . . → Read More: Trial Underway Testing Psychedelic Drug for Depression
By Alan, on March 21st, 2023%
A developer of mental health therapies from psychedelic compounds says it received FDA clearance for a clinical trial testing low doses of psilocybin. . . . → Read More: Trial to Test Low-Dose Psilocybin for Mental Distress
By Alan, on March 17th, 2023%
A new study validates standard electronic instrument measures of healthy individuals and people with schizophrenia to enable reliable clinical trials for treating the disease. . . . → Read More: Standard Electronic Biomarkers Validated for Schizophrenia
By Alan, on March 7th, 2023%
A clinical trial is underway assessing virtual reality interventions for relieving distress and improve the quality of life for cancer patients receiving bone marrow transplants. . . . → Read More: Trial Testing VR to Relieve Cancer Patient Distress
By Alan, on March 4th, 2023%
A group of industry and academic researchers at a scientific meeting displayed advances in technology to improve access to therapy for people with mental disorders. . . . → Read More: Technology Showcased to Ease Mental Health Interventions
By Alan, on February 23rd, 2023%
A new company is underway developing drugs to treat PTSD and other disorders with psychoactive compounds claimed to be safer than current psychedelics. . . . → Read More: Psychoactive Drug Start-Up Raises $40M in Early Funds
By Alan, on January 20th, 2023%
A small clinical trial shows psychotherapy with the psychedelic drug MDMA generates brain signals that help relieve symptoms in people with post-traumatic stress disorder. . . . → Read More: Psychedelic Drug Shown to Relieve PTSD Brain Signals
By Alan, on December 13th, 2022%
Two developers of virtual reality therapy technology for mental health disorders are combining their operations, and raising $13 million in venture funds. . . . → Read More: Mental Health VR Companies Merge, Raise $13M
By Alan, on December 30th, 2021%
A clinical trial is underway testing an experimental drug to treat the underlying causes and symptoms of post-traumatic stress disorder or PTSD. . . . → Read More: Trial Underway Testing PTSD Drug Therapy
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|